Opportunity Information: Apply for CDC RFA PS14 141403CONT16
Apply for CDC RFA PS14 141403CONT16
- The HHS-CDC-NCHHSTP in the health sector is offering a public funding opportunity titled "Collaborations to Improve Identification and Care for Chronic Hepatitis B Virus (HBV) Infection among Persons in the United States who were Born in Countries with Intermediate-High (≥2%) HBV Prevalence" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.270.
- This funding opportunity was created on Apr 25, 2016 and posted on Apr 25, 2016.
- Applicants must submit their applications by Jun 02, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This funding opportunity, titled "Collaborations to Improve Identification and Care for Chronic Hepatitis B Virus (HBV) Infection among Persons in the United States who were Born in Countries with Intermediate-High (>=2%) HBV Prevalence," is a CDC cooperative agreement continuation focused on improving public health efforts related to chronic hepatitis B in the United States. The central aim is to strengthen and expand collaborations that help identify people living with chronic HBV infection and link them to appropriate medical care, with a specific emphasis on U.S. residents who were born in countries where hepatitis B prevalence is considered intermediate to high (at least 2%). In practical terms, the opportunity is designed to support activities that increase testing, diagnosis, and follow-up care for a population that is disproportionately affected due to higher HBV prevalence in many countries of origin and the likelihood of infection occurring earlier in life.
The award is administered by the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (HHS-CDC), through NCHHSTP (the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention). The program uses a cooperative agreement funding instrument, which generally means CDC expects to have substantial involvement in the program beyond simply providing funds, such as technical assistance, alignment with national strategies, and coordination or monitoring of outcomes. The listing indicates this is a continuation opportunity (Opportunity Category: Continuation), suggesting it is meant to continue or extend existing work under prior funding rather than start a completely new, open competition. The funding opportunity number is CDC RFA PS14-141403CONT16, and it is classified under the Health funding activity category with CFDA number 93.270, which corresponds to CDC programs in prevention and control areas, including viral hepatitis-related public health initiatives.
The target population is clearly defined: people in the United States who were born in countries with intermediate-high HBV prevalence (>=2%). This framing reflects a public health strategy that focuses on epidemiologic risk rather than broad, untargeted screening, aiming to efficiently find undiagnosed chronic HBV infections and prevent severe outcomes. Chronic hepatitis B can be asymptomatic for years while causing ongoing liver damage; without diagnosis and monitoring, individuals can progress to cirrhosis, liver failure, or hepatocellular carcinoma. Improving identification and care typically implies a connected set of interventions: culturally and linguistically appropriate community outreach, increased access to HBV testing and interpretation of results, vaccination of susceptible contacts when appropriate, confirmatory evaluation for those who test positive, and referral or linkage to clinicians who can provide long-term monitoring and antiviral therapy when indicated.
Because the opportunity title explicitly emphasizes "collaborations," the program is oriented toward partnerships that join public health agencies, community-based organizations, healthcare systems, and providers serving immigrant and diaspora communities. In many HBV-affected communities, barriers to diagnosis and care can include limited access to healthcare, lack of insurance, language barriers, stigma, and unfamiliarity with the U.S. healthcare system. A collaboration model typically aims to reduce these barriers by coordinating services and building trust through community networks, ensuring that testing leads to real clinical follow-up rather than ending at the point of diagnosis. The continuation nature of the funding suggests CDC is supporting ongoing collaborative infrastructure and proven approaches that can demonstrate measurable progress in identifying individuals with chronic HBV and getting them into appropriate care pathways.
From the administrative details provided, the opportunity was created and posted on April 25, 2016, with an original and current closing date of June 2, 2016. The eligible applicants field is listed as "Others (see text field entitled Additional Information on Eligibility for clarification)," which usually indicates eligibility is limited to certain pre-identified entities, current awardees, or organizations meeting specific criteria laid out in the full announcement. The "Award Ceiling: 0" and blank expected awards field commonly appear in listings where the exact award amounts are not shown in the summary record or are determined under continuation conditions rather than competed as new awards.
Overall, this grant opportunity is best understood as a CDC-backed continuation cooperative agreement intended to sustain and refine partner-driven strategies to find undiagnosed chronic hepatitis B infections among U.S. residents born in higher-prevalence countries and to improve their linkage to ongoing clinical care. The emphasis is on practical, coordinated public health action: getting the right people tested, ensuring results are followed by appropriate medical evaluation, and building durable referral and care systems so chronic HBV is managed in ways that reduce liver disease complications and prevent avoidable deaths.
Frequently Asked Questions (FAQs)
What is the title of this funding opportunity?
The opportunity is titled "Collaborations to Improve Identification and Care for Chronic Hepatitis B Virus (HBV) Infection among Persons in the United States who were Born in Countries with Intermediate-High (>=2%) HBV Prevalence."
What is the main purpose of this opportunity?
The central purpose is to strengthen and expand collaborations that help identify people living with chronic hepatitis B (HBV) infection and link them to appropriate medical care, with a specific focus on U.S. residents who were born in countries where HBV prevalence is intermediate to high (at least 2%).
Which federal agency is administering the award?
The award is administered by the U.S. Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC), through NCHHSTP (the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention).
What type of funding instrument is being used?
This opportunity uses a cooperative agreement. That generally means CDC expects substantial involvement in the program beyond providing funds, such as technical assistance, coordination, alignment with national strategies, and monitoring of outcomes.
Is this a new competitive grant or a continuation?
It is listed as a continuation opportunity (Opportunity Category: Continuation). This indicates it is intended to continue or extend existing work under prior funding rather than operate as a completely new, open competition.
What is the funding opportunity number?
The funding opportunity number is CDC RFA PS14-141403CONT16.
What is the CFDA number associated with this opportunity?
The CFDA number is 93.270, which corresponds to CDC prevention and control program areas, including public health initiatives related to viral hepatitis.
What population is specifically emphasized in this program?
The program emphasizes people in the United States who were born in countries with intermediate-high HBV prevalence (defined here as at least 2%). The approach reflects an epidemiology-based strategy that focuses on higher-likelihood risk groups to improve identification of undiagnosed chronic HBV infection.
Why does the opportunity focus on people born in countries with HBV prevalence of at least 2%?
The information provided indicates this population is disproportionately affected due to higher HBV prevalence in many countries of origin and the likelihood that infection can occur earlier in life. Targeting this group is intended to improve the efficiency and impact of testing, diagnosis, and follow-up care.
What kinds of activities does the opportunity aim to support?
Based on the description, supported activities are those that increase HBV testing, diagnosis, and follow-up care. The narrative also describes related components often involved in improving identification and care, such as community outreach that is culturally and linguistically appropriate, access to HBV testing and interpretation of results, evaluation for those who test positive, and referral or linkage to clinicians for long-term monitoring and treatment when indicated.
What does "collaborations" mean in the context of this opportunity?
The opportunity is oriented toward partnerships that connect public health agencies, community-based organizations, healthcare systems, and providers serving immigrant and diaspora communities. The collaboration model is intended to coordinate services, reduce barriers, and ensure that testing leads to real clinical follow-up rather than stopping at diagnosis.
What public health problem is this opportunity trying to address?
It aims to improve identification and care for chronic hepatitis B infection. Chronic HBV can be asymptomatic for years while causing ongoing liver damage, and without diagnosis and monitoring it can progress to serious outcomes such as cirrhosis, liver failure, or hepatocellular carcinoma.
What barriers to testing and care are noted for HBV-affected communities?
The description notes barriers including limited access to healthcare, lack of insurance, language barriers, stigma, and unfamiliarity with the U.S. healthcare system. Collaborations are positioned as a way to reduce these obstacles through coordinated, trusted community and healthcare networks.
How does this opportunity connect testing to medical care?
The stated goal is not only to increase identification of chronic HBV infection, but also to link people who test positive to appropriate medical care. The description emphasizes that a collaboration model should help ensure testing leads to clinical evaluation, referral, and ongoing monitoring or therapy when indicated.
What is meant by "linkage to care" here?
In this context, linkage to care refers to connecting individuals identified with chronic HBV infection to clinicians or healthcare systems that can provide appropriate evaluation, long-term monitoring, and antiviral therapy when indicated, rather than leaving individuals only with a test result.
When was this opportunity posted, and what was the closing date?
The listing states the opportunity was created and posted on April 25, 2016. The original and current closing date shown is June 2, 2016.
Who is eligible to apply according to the listing?
The eligible applicants field is listed as "Others (see text field entitled Additional Information on Eligibility for clarification)." This typically indicates eligibility may be limited to certain pre-identified entities, current awardees, or organizations meeting criteria described in the full announcement, but the summary text provided does not specify the exact eligible entities.
Does the summary indicate the award amount or number of expected awards?
The summary shows "Award Ceiling: 0" and indicates the expected awards field is blank. The description suggests this may occur when exact award amounts are not shown in the summary record or when amounts are determined under continuation conditions rather than through a new competitive process.
What funding activity category is used for this opportunity?
The opportunity is classified under the Health funding activity category.
What is the overall goal of continuing this cooperative agreement?
The overall goal, as described, is to sustain and refine partner-driven strategies to find undiagnosed chronic HBV infections among U.S. residents born in higher-prevalence countries and improve linkage to ongoing clinical care, with an emphasis on coordinated public health action and durable referral and care systems.
Browse more opportunities from the same category: Health
Next opportunity: South Carolina Conservation Innovation Grants
Previous opportunity: Pre-Solicitation Notice - Inclusion of Individuals with Disabilities in U.S. Foreign Policy
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA PS14 141403CONT16
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA PS14 141403CONT16) also looked into and applied for these:
| Funding Opportunity |
|---|
| Improving Physical Infrastructure to Enhance Animal Model Research: Revisions of Research Project Grants (R24) Apply for RFA OD 16 009 Funding Number: RFA OD 16 009 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Enhanced State Surveillance of Opioid-Involved Morbidity and Mortality Apply for CDC RFA CE16 1608 Funding Number: CDC RFA CE16 1608 Agency: HHS-CDC-NCIPC Category: Health Funding Amount: $775,000 |
| Continuing Enhanced National Surveillance for Prion Diseases in the United States Apply for CDC RFA CK12 120805CONT16 Funding Number: CDC RFA CK12 120805CONT16 Agency: HHS-CDC-NCEZID Category: Health Funding Amount: Case Dependent |
| NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22) Apply for PAR 16 220 Funding Number: PAR 16 220 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) Apply for PAR 16 219 Funding Number: PAR 16 219 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Immunization Information Systems (IIS) Capacity and Operations Support Apply for CDC RFA IP15 150102CONT16 Funding Number: CDC RFA IP15 150102CONT16 Agency: HHS-CDC-NCIRD Category: Health Funding Amount: Case Dependent |
| Advancing the development and licensure of vaginal rings and innovative systemic methods for prevention of HIV infection in women Apply for APS OAA 16 000002 Funding Number: APS OAA 16 000002 Agency: USAID Category: Health Funding Amount: Case Dependent |
| Improving Effectiveness of the Tuberculosis Prevention and Control Programs in Resource Limited Countries Apply for CDC RFA PS14 141103CONT16 Funding Number: CDC RFA PS14 141103CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Promoting CDC's Cancer Surveillance Data Through Workforce Development and Education Apply for CDC RFA DP16 1605 Funding Number: CDC RFA DP16 1605 Agency: HHS-CDC-NCCDPHP Category: Health Funding Amount: $200,000 |
| Engaging Communities in Responding to Zika Under the Integrating Community Health APS Apply for APS OAA 15 000004 ADDENDUM2ZIKA Funding Number: APS OAA 15 000004 ADDENDUM2ZIKA Agency: USAID Category: Health Funding Amount: Case Dependent |
| PPHF 2016: Increasing HPV Vaccine Coverage by Strengthening Adolescent AFIX Activities, Financed in Part by 2016 Prevention and Public Health Funds Apply for CDC RFA IP16 1608PPHF16 Funding Number: CDC RFA IP16 1608PPHF16 Agency: HHS-CDC-NCIRD Category: Health Funding Amount: $500,000 |
| Medical Professionals Recruitment and Continuing Education Program Apply for HHS 2016 IHS HPR 0001 Funding Number: HHS 2016 IHS HPR 0001 Agency: HHS-IHS Category: Health Funding Amount: $105,000 |
| Improving Access to Care: Using Community Health Workers to Improve Linkage and Retention in HIV Care Apply for HRSA 16 185 Funding Number: HRSA 16 185 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Community Health Projects Related to Contamination at Brownfield/Land Reuse Sites Apply for CDC RFA TS16 1602 Funding Number: CDC RFA TS16 1602 Agency: HHS-CDC-ATSDR Category: Health Funding Amount: $150,000 |
| 2016 Senior Companion Program (SCP) Indian Tribes, Native Hawaiians, and Pacific Islanders Competition Apply for CNCS 05 04 2016 SCP Funding Number: CNCS 05 04 2016 SCP Agency: CNCS Category: Health Funding Amount: Case Dependent |
| Aging Research to Address Health Disparities (Admin Supplement) Apply for PA 16 225 Funding Number: PA 16 225 Agency: HHS-NIH11 Category: Health Funding Amount: $45,500 |
| AHRQ Mentored Research Scientist Research Career Development Award (K01) Apply for PA 16 223 Funding Number: PA 16 223 Agency: HHS-AHRQ Category: Health Funding Amount: Case Dependent |
| Improving Physical Infrastructure to Enhance Animal Model Research: Revisions of Research Project Grants (R01) Apply for RFA OD 16 008 Funding Number: RFA OD 16 008 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Leadership Training for People of Color Living with HIV Apply for HRSA 16 186 Funding Number: HRSA 16 186 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Clinical Sequencing Evidence-Generating Research (CSER2) - Coordinating Center (U24) Apply for RFA HG 16 012 Funding Number: RFA HG 16 012 Agency: HHS-NIH11 Category: Health Funding Amount: $645,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA PS14 141403CONT16", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.